Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.52 |
| ▸ | TYR | P14679 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | F3 | P13726 | 2/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 6/20 | 0.50 |
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | CA7 | P43166 | 6/20 | 0.50 |
| ▸ | CA9 | Q16790 | 6/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.50 |
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | CA4 | P22748 | 4/20 | 0.50 |
| ▸ | CA6 | P23280 | 4/20 | 0.50 |
| ▸ | CA5A | P35218 | 4/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL76731 | 1.00 | APP (0.52) | APPTYRKDM4EALDH1A1MAPT | |
| SCHEMBL2821449 | 1.00 | APP (0.52) | APPTYRKDM4EALDH1A1MAPT | |
| SCHEMBL3715296 | 0.78 | CYP2A6 (0.44) | TYRKDM4EALDH1A1KMT2AHSD17B10 | |
| SCHEMBL3715295 | 0.78 | CYP2A6 (0.44) | TYRKDM4EALDH1A1KMT2AHSD17B10 | |
| SCHEMBL2339964 | 0.76 | CYP2C19 (0.42) | KDM4EALDH1A1MAPTCYP2C9CYP2D6 | |
| SCHEMBL2342481 | 0.76 | CYP1A2 (0.50) | ALDH1A1MAPTMAOBPTGS2LMNA | |
| SCHEMBL5332130 | 0.76 | ESR1 (0.57) | APPTYRKDM4EALDH1A1MAPT | |
| SCHEMBL11042248 | 0.76 | APP (0.43) | APPKDM4ECA1CA2ABL1 | |
| SCHEMBL3051230 | 0.76 | APP (0.52) | APPALDH1A1MAPTMAOBMEN1 | |
| SCHEMBL11042246 | 0.76 | APP (0.43) | APPKDM4ECA1CA2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271331-A | Gelsemin derivatives, synthesis method and application thereof in inhibiting tumor cell proliferation | 赣江中药创新中心 | 2024-07-02 | — | — | CN | claimed |
| CN-116559458-A | Active natural product target spot identification method based on PROTAC protein targeted degradation technology and PROTAC compound | 沈阳药科大学 | 2023-08-08 | — | — | CN | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| CN-114845699-A | Oral care compositions | 高露洁-棕榄公司 | 2022-08-02 | — | — | CN | claimed |
| CN-114828822-A | Method for improving barrier integrity of gingival tissue | 高露洁-棕榄公司 | 2022-07-29 | — | — | CN | claimed |
| CN-114395566-B | Application of sweet potato ERF transcription factor IbERF4 in promoting synthesis of plant chlorogenic acid substances | 江苏省农业科学院 | 2022-05-24 | — | — | CN | claimed |
| CN-114395566-A | Application of sweet potato ERF transcription factor IbERF4 in promoting synthesis of plant chlorogenic acid substances | 江苏省农业科学院 | 2022-04-26 | — | — | CN | claimed |
| CN-113491703-A | Application of phenylethanoid glycosides compounds and compositions thereof in preparation of drugs for preventing and treating new coronary pneumonia | 中国科学院上海药物研究所 | 2021-10-12 | — | — | CN | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2002004003-A2 | COMPOSITION FOR THE TREATMENT OF OSTEOARTHRITIS | N.V. NUTRICIA (NL) | 2002-01-17 | — | — | WO | claimed |
| US-6323011-B1 | PROVIDING TRANS-FERULIC ACID OR ITS SALT; COMBINING WITH ENZYME ACTIVITY I, ENZYME ACTIVITY II, AND ENZYME ACTIVITY III, WHEREIN ENZYME ACTIVITY I, ENZYME ACTIVITY II, AND ENZYME ACTIVITY III CATALYZE THE PRODUCTION OF VANILLIN | INSTITUTE OF FOOD RESEARCH (GB) | 2001-11-27 | — | — | US | claimed |
| EP-1084269-A1 | NOVEL PEROXIDASE SUBSTRATES AND THEIR USE IN CATALYZED REPORTER DEPOSITION | NEN Life Science Products, Inc. (US) | 2001-03-21 | — | — | EP | claimed |
| EP-0785190-B1 | Quinolinone derivative and antiallergic agent with said quinolinone derivative as the active ingredient | DAINIPPON INK & CHEMICALS (JP) | 2000-08-16 | — | — | EP | claimed |
| WO-1999063108-A1 | NOVEL PEROXIDASE SUBSTRATES AND THEIR USE IN CATALYZED REPORTER DEPOSITION | NEN LIFE SCIENCE PRODUCTS, INC. (US) | 1999-12-09 | — | — | WO | claimed |
| US-5985242-A | PEPTIDE OF 3 TO 5 D-AMINO ACIDS; MAY BE MODIFIED AT AMINO-AND/OR CARBOXY TERMINUS; FOR TREATMENT OF AMYLOIDOSIS, ALZHEIMER'S DISEASE | PRAECIS PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | claimed |
| EP-0929574-A1 | MODULATORS OF beta-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS | Praecis Pharmaceuticals Incorporated (US) | 1999-07-21 | — | — | EP | claimed |
| US-5863748-A | p-Hydroxycinnamoyl-containing substrates for an analyte dependent enzyme activation system | NEW LIFE SCIENCE PRODUCTS, INC. (US) | 1999-01-26 | — | — | US | claimed |
| WO-1998008868-A9 | MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS | — | 1998-05-28 | — | — | WO | claimed |
| WO-1998008868-A1 | MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 1998-03-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | APP 1117/4885TYR 2156/4885KDM4E 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.